-
1.发明公开DELTA-AMINO-GAMMA-HYDROXY-OMEGA-ARYL-ALKANOIC ACID AMIDES AND USE AS RENIN INHIBITORS 审中-公开DELTA氨基GAMMA羟基OMEGA-ARYLALKYLSÄUREAMIDE与应用，肾素抑制剂
公开(公告)号：EP1692095A1
公开(公告)日：2006-08-23
申请号：EP04819639.8
申请日：2004-11-30
申请人： Novartis AG , Novartis Pharma GmbH
IPC分类号： C07C237/22 , A61K31/165
CPC分类号： C07C237/22
摘要： The invention relates to novel δ-amino-Ϝ-hydroxy-ω-aryl-alkanoic acid amides of formula (I), or a pharmaceutically acceptable salt thereof.
-
2.发明公开
公开(公告)号：EP1337527A1
公开(公告)日：2003-08-27
申请号：EP01993604.6
申请日：2001-11-05
申请人： Novartis AG , Novartis Pharma GmbH
发明人： ALBERT, Rainer , COOKE, Nigel, Graham , COTTENS, Sylvain , EHRHARDT, Claus , EVENOU, Jean-Pierre , SEDRANI, Richard , VON MATT, Peter , WAGNER, Jürgen , ZENKE, Gerhard
IPC分类号： C07D403/04 , C07D403/14 , A61K31/404 , A61P29/00 , A61P37/06
CPC分类号： C07D403/14 , A61K45/06 , C07D231/12 , C07D233/56 , C07D249/08 , C07D401/14 , C07D403/04 , C07D471/10
摘要： Indolylmaleimide derivatives comprising either a substituted phenyl, naphthyl, tetrahydronaphthyl, quinazolinyl, quinolyl, isoquinolyl or pyrimidinyl residue have interesting pharmaceutical properties, e.g. in the treatment and/or prevention of T-cell mediated acute or chronic inflammatory diseases or disorders, autoimmune diseases, graft rejection or cancer.
-
公开(公告)号：EP2007788A2
公开(公告)日：2008-12-31
申请号：EP07781535.5
申请日：2007-04-09
申请人： NOVARTIS AG , Novartis Pharma GmbH
发明人： COTTENS, Sylvain , EHRHARDT, Claus , FU, Jiping , PARKER, David Thomas , PATANE, Michael , RADETICH, Branko , RAMAN, Prakash , RANDL, Stefan Andreas , RIGOLLIER, Pascal , SEEPERSAUD, Mohindra , SIMIC, Oliver , WAN, Dongpeng
CPC分类号： C07K5/0812 , A61K38/00 , C07K5/06078 , C07K5/06165 , C07K5/0808 , C07K5/1016
摘要： The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of human diseases.
-
公开(公告)号：EP1007033B1
公开(公告)日：2008-04-23
申请号：EP98951317.1
申请日：1998-08-26
申请人： Novartis AG , Novartis Pharma GmbH
发明人： BAUER, Wilfried , COTTENS, Sylvain , GEYL, Dieter , WEITZ-SCHMIDT, Gabriele , KALLEN, Jörg , HOMMEL, Ulrich
IPC分类号： A61K31/365 , A61K31/22 , A61K31/19 , A61K31/44 , C07D309/10 , C07D309/30 , C07D319/06 , C07D213/64
CPC分类号： C07D213/64 , A61K31/00 , A61K31/222 , A61K31/366 , C07C219/24 , C07C235/30 , C07C237/18 , C07C237/22 , C07C2601/08 , C07C2602/28 , C07D207/16 , C07D295/13 , C07D295/145 , C07D295/205 , C07D307/52 , C07D309/10 , C07D309/30 , C07D405/12 , C07D491/10
摘要： The present invention relates to compounds which bind to all or parts of the active binding 'south pole pocket' of the LFA-1 I-domain and their uses as LFA-1 antagonists.
-
5.发明公开
公开(公告)号：EP1836163A2
公开(公告)日：2007-09-26
申请号：EP05825434.3
申请日：2005-12-21
申请人： Novartis AG , Novartis Pharma GmbH
发明人： BREITENSTEIN, Werner , COTTENS, Sylvain , EHRHARDT, Claus , JACOBY, Edgar , LORTHIOIS, Edwige, Liliane, Jeanne , MAIBAUM, Juergen, Klaus , OSTERMANN, Nils , SELLNER, Holger , SIMIC, Oliver
IPC分类号： C07D207/09 , C07D207/14 , C07D401/12 , C07D405/12 , C07D403/12 , C07D409/12 , C07D207/08 , C07D413/12 , C07D417/12 , C07D491/10 , A61K31/40 , A61K31/41 , A61K31/435 , A61K31/54 , A61P9/00
CPC分类号： C07D207/08 , C07D207/09 , C07D207/14 , C07D401/12 , C07D403/12 , C07D405/12 , C07D409/12 , C07D413/12 , C07D417/12 , C07D491/10
摘要： Novel 3-mono-, 3,4-di- and 3,4,4,-tri-substituted pyrrolidine compounds, these compounds for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (= disorder) that depends on inappropriate activity of renin; the use of a compound of that class for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on inappropriate activity of renin; the use of a compound of that class in the treatment of a disease that depends on inappropriate activity of renin; pharmaceutical formulations comprising a said substituted pyrrolidine compound, and/or a method of treatment comprising administering a said substituted pyrrolidine compound, a method for the manufacture of said substituted pyrrolidine compounds, and novel intermediates and partial steps for their synthesis are described. The substituted pyrrolidine compounds are especially of the formula (I), wherein the substituents are as described in the specificacion.
-
公开(公告)号：EP1154988B1
公开(公告)日：2004-08-11
申请号：EP00916832.9
申请日：2000-02-14
申请人： Novartis AG , Novartis Pharma GmbH
发明人： BAENTELI, Rolf , BAUER, Wilfried , COTTENS, Sylvain , EHRHARDT, Claus , HOMMEL, Ulrich , KALLEN, Jörg , MEINGASSNER, Josef, Gottfried , NUNINGER, François , WEITZ-SCHMIDT, Gabriele
IPC分类号： C07C235/26 , C07C237/18 , C07C235/30 , C07C237/20 , C07D211/76 , C07D265/24 , C07D401/06 , A61K31/4402 , A61K31/45 , A61K31/4545 , A61K31/535 , A61P9/10 , A61P3/06 , A61P29/00 , A61P37/00
CPC分类号： C07C271/12 , C07C235/26 , C07C235/30 , C07C237/18 , C07C2602/28 , C07D211/76 , C07D265/10
摘要： Mevinolin derivatives wherein the lactone ring is modified have interesting pharmaceutical properties, particularly in preventing or treating disorders or diseases mediated by LFA-1/ICAM-1 interactions.
-
公开(公告)号：EP1337527B1
公开(公告)日：2009-10-14
申请号：EP01993604.6
申请日：2001-11-05
申请人： Novartis AG , Novartis Pharma GmbH
发明人： ALBERT, Rainer , COOKE, Nigel, Graham , COTTENS, Sylvain , EHRHARDT, Claus , EVENOU, Jean-Pierre , SEDRANI, Richard , VON MATT, Peter , WAGNER, Jürgen , ZENKE, Gerhard
IPC分类号： C07D403/04 , C07D403/14 , A61K31/404 , A61P29/00 , A61P37/06
CPC分类号： C07D403/14 , A61K45/06 , C07D231/12 , C07D233/56 , C07D249/08 , C07D401/14 , C07D403/04 , C07D471/10
摘要： Indolylmaleimide derivatives comprising either a substituted phenyl, naphthyl, tetrahydronaphthyl, quinazolinyl, quinolyl, isoquinolyl or pyrimidinyl residue have interesting pharmaceutical properties, e.g. in the treatment and/or prevention of T-cell mediated acute or chronic inflammatory diseases or disorders, autoimmune diseases, graft rejection or cancer.
摘要翻译： 包含取代的苯基，萘基，四氢萘基，喹唑啉基，喹啉基，异喹啉基或嘧啶基残基的吲哚基马来酰亚胺衍生物具有令人感兴趣的药学性质， 用于治疗和/或预防T细胞介导的急性或慢性炎性疾病或病症，自身免疫性疾病，移植排斥或癌症。
-
公开(公告)号：EP1377593B1
公开(公告)日：2005-12-28
申请号：EP02727484.4
申请日：2002-03-26
申请人： Novartis AG , Novartis Pharma GmbH
发明人： ALBERT, Rainer , BAUMRUKER, Thomas , BRINKMANN, Volker , COTTENS, Sylvain , PAPAGEORGIOU, Christos , PRIESCHL-STRASSMAYR, Eva, Erika , HINTERDING, Klaus
IPC分类号： C07F9/09 , A61K31/661 , A61K31/137 , A61P31/00 , A61P17/00 , C07C225/16 , C07C271/16 , C07C217/64 , A61P19/00
CPC分类号： C07F9/65744 , C07B2200/07 , C07C217/64 , C07C225/16 , C07C271/16 , C07C2601/14 , C07F9/094 , C07F9/113 , C07F9/12
摘要： Compounds of formula (I), wherein m, R, R1 and R3 to R6 are as defined in the specification, m, is 1, 2 or 3 and X is O or a direct bond, and the corresponding unphosporylated compounds have interesting properties, e.g. immunosuppressive properties.
摘要翻译： 其中m，R，R 1和R 3至R 6的式I化合物如说明书中所定义，m为1， 2或3，X是O或直接键合，并且相应的未磷酸化化合物具有有趣的性质，例如 免疫抑制性质。
-
公开(公告)号：EP0941082B1
公开(公告)日：2004-09-15
申请号：EP97951219.1
申请日：1997-11-17
申请人： Novartis AG , Novartis Pharma GmbH
IPC分类号： A61K31/00 , A61K31/135 , A61K31/13 , A61P37/00 , A61P43/00
CPC分类号： A61K31/13 , A61K31/131 , A61K31/133 , A61K31/137 , A61K31/436 , A61K39/395 , A61K2300/00
摘要： Use of a compound of formula (I) wherein R1 is an optionally substituted straight- or branched carbon chain having 12 to 22 carbon atoms which may be optionally interrupted by an optionally substituted phenylene, and each of R2, R3, R4 and R5, independently, is H or lower alkyl, in free form or in pharmaceutically acceptable salt form, in the prevention or treatment of chronic rejection in a recipient of organ or tissue allo- or xenotransplant, or of acute rejection in a xenograft transplant recipient.
-
公开(公告)号：EP1377593A2
公开(公告)日：2004-01-07
申请号：EP02727484.4
申请日：2002-03-26
申请人： Novartis AG , Novartis Pharma GmbH
发明人： ALBERT, Rainer , BAUMRUKER, Thomas , BRINKMANN, Volker , COTTENS, Sylvain , PAPAGEORGIOU, Christos , PRIESCHL-STRASSMAYR, Eva, Erika , HINTERDING, Klaus
IPC分类号： C07F9/09 , A61K31/661 , A61K31/137 , A61P31/00 , A61P17/00 , C07C225/16 , C07C271/16 , C07C217/64 , A61P19/00
CPC分类号： C07F9/65744 , C07B2200/07 , C07C217/64 , C07C225/16 , C07C271/16 , C07C2601/14 , C07F9/094 , C07F9/113 , C07F9/12
摘要： Compounds of formula (I), wherein m, R, R1 and R3 to R6 are as defined in the specification, m, is 1, 2 or 3 and X is O or a direct bond, and the corresponding unphosporylated compounds have interesting properties, e.g. immunosuppressive properties.
-
-
-
-
-
-
-
-
-
搜索结果
23 条记录 (耗时 0.03 秒)
